Vascular Effects of Sertraline in Heart Failure

NCT00585455 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2009-07-23

No results posted yet for this study

Summary

To determine the effects of chronic sertraline treatment on brachial artery flow-mediated dilation in patients with chronic heart failure and depression

Conditions

Interventions

DRUG

sertraline

open label 25-50 mg daily as tolerated

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY
  • Yale University

    lead OTHER

Principal Investigators

  • Stuart Katz, MD · Yale University

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585455 on ClinicalTrials.gov